FDA计划针对咖啡因粉末采取强硬措施
出自识林
FDA计划针对咖啡因粉末采取强硬措施
笔记 2014-12-29 Lachman CONSULTANTS 我们知道许多获批产品含有咖啡因。一些止疼药中，咖啡因用来作为缓解疼痛的佐药。咖啡因还用来作为治疗婴幼儿呼吸暂停的获批注射剂和口服溶液。在食品中被监管（尤其是苏打饮料中），也会出现在某些OTC产品中，如“瞌睡无”，较低控制剂量用来帮助从疲劳中恢复精神。但现在，最近发表在雅虎健康的一篇美联社文章（FDA Going After Sellers of Pure Caffeine Powder）指出，FDA正准备一场法律诉讼以减少咖啡因粉末作为膳食补充剂销售。文章解释道，这类产品可能是致命的，咖啡因过量和中毒的症状可能包括“心跳加速或不规律、癫痫、呕吐、腹泻和定向障碍。” FDA正在针对这类产品制定法律和监管策略。有人会认为，在俄亥俄州至少一名少年死亡后，那些销售这些产品的商家会重新考虑其行为。咖啡因是一种兴奋剂，即使小剂量使用也可能是致命的。可获得纯咖啡因粉的问题是，那些使用的人可能并不知道其巨大的威力。对于年轻人、老年人或那些有心脏问题或高血压患者尤其严重。 我们很乐意看到FDA的法律手段以及如何快速衔接，期待在更多使用者受到伤害之前看到FDA的执法行动。 Lachman CONSULTANTS - Bob Pollock先生 2014-12-29 The Ups and Downs of Caffeine – FDA to Get Tough? We know that there are a number of approved products that contain caffeine. Some are pain medications where it is used as an adjuvant to improve pain relief. It is used as an approved injection and oral solution for treatment of apnea in infants. It is regulated in foods (particularly in beverages like soda) and is available in certain OTC products, like No-Doz, for help in restoring mental alertness from fatigue in low controlled doses. But now, as noted in a recent article by the Associated Press found on Yahoo health (here), the FDA is gearing up for a legal battle to reduce the availability of caffeine powder being sold as a dietary supplement. As explained in the article referenced above, the product can be deadly and symptoms of caffeine overdose and toxicity can include “rapid or erratic heartbeat, seizures, vomiting, diarrhea and disorientation.” The FDA is developing a legal and regulatory strategy for dealing with this product. One would think that, after the death on at least one teenager in Ohio, those that are selling the product would rethink their actions. Caffeine is a stimulant and can be fatal, even in small doses. The problem with the availability of pure caffeine powder is that those that use the product may not be aware of its powerful effects. This may be especially problematic for the young, elderly or for those with cardiac problems or hypertension. It will be interesting to see the FDA's legal approach and how fast it is articulated but expect FDA enforcement action to be swift before too many more users are injured. |